{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:00:48Z","timestamp":1787068848674,"version":"build-2736575974"},"posted":{"date-parts":[[2025,3,11]]},"group-title":"Molecular Biology","reference-count":38,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Multiple myeloma (MM), a clonal plasma cell disorder is the second most frequent hematological malignancy in the United States. This malignancy is characterized by a series of symptoms such as bone lesions, hypercalcemia, renal failure, and anemia. The current clinical drugs in the market are successful in treating multiple myeloma patients into remission but does not address relapse where a more aggressive phenotype of the cancer remains untreatable. We hypothesize that a small subset of multiple myeloma stem-like cells (MMSLC\u2019s) that overexpress aldehyde dehydrogenases (ALDH\n                  <jats:sup>+<\/jats:sup>\n                  ) is the cause of the relapse. Overexpression of ALDH bolsters drug resistance via detoxification and stemness via the retinoic acid signaling pathway. The phenotype of MMSLC\u2019s is not yet known for certainty but there are a few well established markers such CD138 negative (CD138\n                  <jats:sup>neg<\/jats:sup>\n                  ) cells that are known to overexpress ALDH. In this study, we target regular MM cells and bortezomib resistant ALDH\n                  <jats:sup>+<\/jats:sup>\n                  \/CD138\n                  <jats:sup>neg<\/jats:sup>\n                  MMSLC\u2019s with a novel, potent, pan-ALDH inhibitor, KS100. Here we report KS100 effectively lowered ALDH expression in regular and bortezomib resistant ALDH\n                  <jats:sup>+<\/jats:sup>\n                  \/CD138\n                  <jats:sup>neg<\/jats:sup>\n                  cells, MM cell viability as well as proteins associated with MMSLC\u2019s. Most importantly we showed that KS100 lowered ALDH\n                  <jats:sup>+<\/jats:sup>\n                  populations in regular, bortezomib resistant and CD138\n                  <jats:sup>neg<\/jats:sup>\n                  cells via ALDEFLUOR\u2122 assay.\n                <\/jats:p>","DOI":"10.1101\/2025.03.06.641909","type":"posted-content","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:47:29Z","timestamp":1741841249000},"source":"Crossref","is-referenced-by-count":1,"title":["Novel Pan-ALDH Inhibitor KS100 Effectively Targets ALDH+\/CD138\u207b Stem-like Cells to Overcome Relapse in Multiple Myeloma"],"prefix":"10.64898","author":[{"given":"Robert","family":"Chitren","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ"},{"name":"Department of Science and Mathematics, Rowan University, Glassboro, NJ; a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishne","family":"Gowda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantu","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash","family":"Jonnalagadda","sequence":"additional","affiliation":[{"name":"Department of Science and Mathematics, Rowan University, Glassboro, NJ; a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulin","family":"Budak-Alpdogan","sequence":"additional","affiliation":[{"name":"Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health University, Camden, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026041100021879000_2025.03.06.641909v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"2026041100021879000_2025.03.06.641909v1.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"2026041100021879000_2025.03.06.641909v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26951-z"},{"key":"2026041100021879000_2025.03.06.641909v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2013.04.005"},{"key":"2026041100021879000_2025.03.06.641909v1.5","doi-asserted-by":"crossref","unstructured":"Pinto, V. , et al., Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers (Basel), 2020. 12(2).","DOI":"10.3390\/cancers12020407"},{"key":"2026041100021879000_2025.03.06.641909v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111962"},{"key":"2026041100021879000_2025.03.06.641909v1.7","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2166035"},{"key":"2026041100021879000_2025.03.06.641909v1.8","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26885"},{"key":"2026041100021879000_2025.03.06.641909v1.9","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.6.697"},{"key":"2026041100021879000_2025.03.06.641909v1.10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01039"},{"key":"2026041100021879000_2025.03.06.641909v1.11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1145"},{"key":"2026041100021879000_2025.03.06.641909v1.12","doi-asserted-by":"crossref","unstructured":"Osmond, B. , et al., HOXA9 Overexpression Contributes to Stem Cell Overpopulation That Drives Development and Growth of Colorectal Cancer. Int J Mol Sci, 2022. 23(12).","DOI":"10.3390\/ijms23126799"},{"key":"2026041100021879000_2025.03.06.641909v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.350"},{"key":"2026041100021879000_2025.03.06.641909v1.14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26157"},{"issue":"1","key":"2026041100021879000_2025.03.06.641909v1.15","first-page":"72","article-title":"ROS activated prodrug for ALDH overexpressed cancer stem cells","volume":"58","year":"2021","journal-title":"Chem Commun (Camb"},{"key":"2026041100021879000_2025.03.06.641909v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111962"},{"issue":"2","key":"2026041100021879000_2025.03.06.641909v1.17","first-page":"381","article-title":"[Immunophenotype characteristics in multiple myeloma cells and their significance]","volume":"18","year":"2010","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2026041100021879000_2025.03.06.641909v1.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092378"},{"issue":"1","key":"2026041100021879000_2025.03.06.641909v1.19","first-page":"19","article-title":"Role of Stem Cells in Colorectal Cancer Progression and Prognostic and Predictive Characteristics of Stem Cell Markers in Colorectal Cancer","volume":"12","year":"2017","journal-title":"Curr Stem Cell Res Ther"},{"key":"2026041100021879000_2025.03.06.641909v1.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-018-9444-y"},{"key":"2026041100021879000_2025.03.06.641909v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1692-y"},{"key":"2026041100021879000_2025.03.06.641909v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2014.12.008"},{"key":"2026041100021879000_2025.03.06.641909v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.78"},{"key":"2026041100021879000_2025.03.06.641909v1.24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.894535"},{"key":"2026041100021879000_2025.03.06.641909v1.25","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-010-9208-4"},{"key":"2026041100021879000_2025.03.06.641909v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2017.06.003"},{"key":"2026041100021879000_2025.03.06.641909v1.27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M004987200"},{"key":"2026041100021879000_2025.03.06.641909v1.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3096"},{"key":"2026041100021879000_2025.03.06.641909v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.08.009"},{"key":"2026041100021879000_2025.03.06.641909v1.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167323"},{"key":"2026041100021879000_2025.03.06.641909v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.08.003"},{"key":"2026041100021879000_2025.03.06.641909v1.32","doi-asserted-by":"crossref","unstructured":"Kellner, J. , et al., Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s. JCI Insight, 2019. 4(7).","DOI":"10.1172\/jci.insight.124698"},{"key":"2026041100021879000_2025.03.06.641909v1.33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1254612"},{"key":"2026041100021879000_2025.03.06.641909v1.34","doi-asserted-by":"crossref","unstructured":"Facey, C.O.B. , et al., CYP26A1 Links WNT and Retinoic Acid Signaling: A Target to Differentiate ALDH+ Stem Cells in APC-Mutant CRC. Cancers (Basel), 2024. 16(2).","DOI":"10.3390\/cancers16020264"},{"key":"2026041100021879000_2025.03.06.641909v1.35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1182204"},{"key":"2026041100021879000_2025.03.06.641909v1.36","doi-asserted-by":"crossref","unstructured":"Mezquita, B. and C. Mezquita , Two Opposing Faces of Retinoic Acid: Induction of Stemness or Induction of Differentiation Depending on Cell-Type. Biomolecules, 2019. 9(10).","DOI":"10.3390\/biom9100567"},{"key":"2026041100021879000_2025.03.06.641909v1.37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1497"},{"key":"2026041100021879000_2025.03.06.641909v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0018-y"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.03.06.641909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:02:27Z","timestamp":1775890947000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.03.06.641909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1101\/2025.03.06.641909","relation":{},"subject":[],"published":{"date-parts":[[2025,3,11]]},"subtype":"preprint"}}